Castle Biosciences Announces First Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Castle Biosciences Inc. (CSTL) Tops Q1 EPS by 18c
May 11, 2020 5:01 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q1 EPS of $0.03, $0.18 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $17.4 million versus the consensus estimate of $13.79 million.
The Castle Biosciences team continued to perform at an exceptional level in the first quarter, with significant growth in revenue and DecisionDx®-Melanoma test report volume, said Derek Maetzold, president and chief executive officer. We are making investments in our business intended to put us in a position of strength as we continue to move through the current COVID-19 situation and execute on our... More
